Article

Comorbid depression, chronic pain, and disability in primary care

Department of Psychiatry and Behavioral Sciences, University School of Medicine, Stanford, CA, USA.
Psychosomatic Medicine (Impact Factor: 4.09). 03/2006; 68(2):262-8. DOI: 10.1097/01.psy.0000204851.15499.fc
Source: PubMed

ABSTRACT The objectives of this study were to provide estimates of the prevalence and strength of association between major depression and chronic pain in a primary care population and to examine the clinical burden associated with the two conditions, singly and together.
A random sample of Kaiser Permanente patients who visited a primary care clinic was mailed a questionnaire assessing major depressive disorder (MDD), chronic pain, pain-related disability, somatic symptom severity, panic disorder, other anxiety, probable alcohol abuse, and health-related quality of life (HRQL). Instruments included the Patient Health Questionnaire, SF-8, and Graded Chronic Pain Questionnaire. A total of 5808 patients responded (54% of those eligible to participate).
Among those with MDD, a significantly higher proportion reported chronic (i.e., nondisabling or disabling) pain than those without MDD (66% versus 43%, respectively). Disabling chronic pain was present in 41% of those with MDD versus 10% of those without MDD. Respondents with comorbid depression and disabling chronic pain had significantly poorer HRQL, greater somatic symptom severity, and higher prevalence of panic disorder than other respondents. The prevalence of probable alcohol abuse/dependence was significantly higher among persons with MDD compared with individuals without MDD regardless of pain or disability level. Compared with participants without MDD, the prevalence of other anxiety among those with MDD was more than sixfold greater regardless of pain or disability level.
Chronic pain is common among those with MDD. Comorbid MDD and disabling chronic pain are associated with greater clinical burden than MDD alone.

Download full-text

Full-text

Available from: Christine M Blasey, Aug 04, 2015
1 Follower
 · 
141 Views
  • Source
    • "In fact, emotional aspect is an intrinsic construct of chronic pain, and co-morbid depression is extensively observed in individuals who suffer from chronic neuropathic pain, with the co-occurrence up to 34% (Gustorff et al., 2008). Reciprocally, pain is one of the most common complaints in patients with depression (Arnow et al., 2006; Demyttenaere et al., 2006) and depressive symptoms may exacerbate or predict chronic pain (Burke et al., 2010; Tunks et al., 2008; Wang et al., 2012). The high prevalence of this co-morbidity intensifies the disamenity of neuropathic patients and deteriorates their overall life qualities (Gustorff et al., 2008), which necessitates improved treatment. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Patients suffering from chronic neuropathic pain are at high risk of co-morbid depression, which burdens healthcare. This work aimed to investigate the effects of resveratrol, a phenolic monomer enriched in red wine and grapes, on pain-related and depressive-like behaviors in mice with mononeuropathy, and explored the mechanism(s). Mice received chronic constriction injury (CCI) of sciatic nerves, and sequentially developed pain-related and depressive-like behaviors, as evidenced by sensory hypersensitivity (thermal hyperalgesia in Hargreaves test and mechanical allodynia in von Frey test) and behavioral despair (prolonged immobility time in forced swim test). Chronic treatment of neuropathic mice with resveratrol (30 mg/kg, p.o., twice per day for three weeks) normalized their thermal hyperalgesia (but not mechanical allodynia) and depressive-like behaviors, and these actions were abolished by chemical depletion of central serotonin (5-HT) but potentiated by co-treatment with 5-HTP, a precursor of 5-HT. The anti-hyperalgesia and anti-depression exerted by resveratrol may be pharmacologically segregated, since intrathecal (i.t.) and intracerebroventricular (i.c.v.) injection of methysergide, a non-selective 5-HT receptor antagonist, separately abrogated the two actions. Furthermore, the antihyperalgesic action of resveratrol was preferentially counteracted by co-administration of the 5-HT7 receptor antagonist SB-258719, while the anti-depression was abrogated by 5-HT1A receptor antagonist WAY-100635. These results confirm that chronic resveratrol administration exerts curative-like effects on thermal hyperalgesia and co-morbid depressive-like behaviors in mice with mononeuropathy. Spinal and supraspinal serotonergic systems (coupled with 5-HT7 and 5-HT1A receptors, respectively) are differentially responsible for the antihyperalgesic and antidepressant-like properties of resveratrol.
    Neuropharmacology 05/2014; 85. DOI:10.1016/j.neuropharm.2014.04.021 · 4.82 Impact Factor
  • Source
    • "al relationships to social support , IL - 6 , depressive symptoms , and pain . All primary analyses adjusted for the following covariates , assessed at T2 : body mass index ( BMI : kg / m 2 ) , age , education level , comorbidities , cancer stage , and time since treatment ( Everson et al . , 2002 ; Salgado et al . , 2003 ; Bozcuk et al . , 2004 ; Arnow et al . , 2006 ; Bjer - keset et al . , 2008 ) . The pain analyses also adjusted for pain medication use . Cancer treatment type is largely dictated by the current National Comprehensive Cancer Network ( NCCN ) guidelines , providing reasonable treatment uniformity within each cancer stage ."
    [Show abstract] [Hide abstract]
    ABSTRACT: Objective Pain and depressive symptoms are commonly experienced by cancer survivors. Lower social support is linked to a variety of negative mental and physical health outcomes among survivors. Immune dysregulation may be one mechanism linking low social support to the development of pain and depressive symptoms over time. Accordingly, the goal of the present study was to examine the relationships among survivors’ social support, pain, depressive symptoms, and inflammation. Methods Breast cancer survivors (N = 164, stages 0-IIIA) completed two study visits, one before any cancer treatment and the other 6 months after the completion of surgery, radiation, or chemotherapy, whichever came last. Women completed self-report questionnaires assessing social support, pain, and depressive symptoms, and provided a blood sample at both visits. Results Survivors with lower social support prior to treatment experienced higher levels of pain and depressive symptoms over time than their more socially supported counterparts. Furthermore, women with lower pretreatment social support had higher levels of IL-6 over time, and these elevations in IL-6 predicted marginally larger increases in depressive symptoms. Conclusions The results of this study suggest that social support at the time of diagnosis predicts the post-treatment development of pain, depressive symptoms, and inflammation. Consequently, early interventions targeting survivors’ social networks could improve quality of life during survivorship.
    Psychoneuroendocrinology 04/2014; 42:38-44. DOI:10.1016/j.psyneuen.2013.12.016 · 5.59 Impact Factor
  • Source
    • "This comorbidity leads to serious clinical problems and has a larger negative impact on the quality of life (Arnow et al., 2006; Goldberg and McGee, 2011). Although the mechanisms concerning pain-emotion diseases have not been defined, preclinical studies have demonstrated a relationship between neuropathic pain and mood disorders in animal models (Arnow et al., 2006; Matsuzawa-Yanagida et al., 2008; Yalcin et al., 2011). In fact, previous studies have shown depression-related behavior in rodents subjected to sciatic nerve injury, a well-recognized model for neuropathic pain (Fukuhara et al., 2012; Jesse et al., 2010). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Clinically, it is suggested that chronic pain might induce mood disorders like depression and anxiety. Based on this antidepressant drugs have emerged as a new therapy for pain. In this study, the effect of acute and subchronic treatments with 3-(4-fluorophenylselenyl)-2,5-diphenylselenophene (F-DPS) on behavioral changes induced by partial sciatic nerve ligation (PSNL) was evaluated. At the 4(th) week after surgery, PSNL caused a significant depression-like behavior in mice evaluated in the forced swimming test (FST) and the tail suspension test (TST), which was accompanied by increased pain sensitivity. The anxiety-like behavior assessed in the light-dark test (LDT) was not modified by PSNL. Acute treatment with F-DPS, at a dose of 1 mg/kg, intragastrically (i.g.) administered 30 min before the FST, produced a significant anti-immobility effect in PSNL mice. The antidepressant drug paroxetine showed acute antidepressant-like action at a dose 10 times higher than F-DPS. Subchronic treatment with F-DPS (0.1 mg/kg, i.g.) reversed depression-like behavior of sciatic nerve-ligated mice in the TST and FST and produced a significant anxiolytic-like action in both sham-operated and PSNL animals. Although the acute F-DPS treatment did not produce anti-allodynic effect, F-DPS subchronic treatment significantly reduced pain sensitivity in PSNL mice. These findings demonstrated that F-DPS blocked behavioral changes induced by neuropathic pain, suggesting that it might be attractive in the pharmacological approach of pain-emotion diseases.
    Neuropharmacology 01/2014; 79. DOI:10.1016/j.neuropharm.2014.01.020 · 4.82 Impact Factor
Show more